Last reviewed · How we verify

NCT06849258: RAPID-III

A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms

Recruiting now NA Last updated 27 April 2025
What this trial tests

NA trial testing FloStent in Benign Prostatic Hyperplasia in 215 participants. Currently enrolling.

Timeline
10 February 2025
Primary endpoint
31 December 2032
31 December 2032

Quick facts

Lead sponsorRivermark Medical
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment215
Start date10 February 2025
Primary completion31 December 2032
Estimated completion31 December 2032
Sites20 locations across United States, Australia

Drugs / interventions tested

Conditions studied

Sponsor

Rivermark Medical

Who can join

45 and older, male only, with Benign Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the FloStent). All participants will undergo a flexible cystoscopy and those randomized to the treatment arm will receive the FloStent, while those randomized to the sham arm will not receive the FloStent.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. State-of-the-art in minimally invasive treatments for benign prostatic obstruction.
    Grossmann NC, Berjaoui MB, Choudhary O, Pradere B, et al · · 2026 · PMID 41469901 · DOI 10.4111/icu.20250390

Verify or expand the search:

Other recruiting trials for Benign Prostatic Hyperplasia

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06849258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing